Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I. Haddad, Athanassios Argiris, Maura L. Gillison et al.|Journal of Clinical Oncology|2022Cited by 159
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141Maura L. Gillison, Robert L. Ferris, George R. Blumenschein et al.|The Oncologist|2022Cited by 52